<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28042955</article-id><article-id pub-id-type="pmc">5352387</article-id><article-id pub-id-type="publisher-id">14100</article-id><article-id pub-id-type="doi">10.18632/oncotarget.14100</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Xu</surname><given-names>Xue-Lian</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cheng</surname><given-names>Hao</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Meng-Si</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Hai-Liang</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Rui-Yan</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xuan</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xiu-Min</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mai</surname><given-names>Jia</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Chen-Lu</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jiao</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhi-Ling</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Zhen-Mei</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Rong</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jun-Dong</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Xiao-Feng</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China</aff><aff id="A2"><sup>2</sup> Department of Gynecological Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China</aff><aff id="A3"><sup>3</sup> The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510060, China</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Xiao-Feng Zhu,</italic><email>zhuxf@sysucc.org.cn</email></corresp><corresp id="cor2"><italic>Jun-Dong Li,</italic><email>lijd@sysucc.org.cn</email></corresp></author-notes><pub-date pub-type="collection"><day>31</day><month>1</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2016</year></pub-date><volume>8</volume><issue>5</issue><fpage>8120</fpage><lpage>8130</lpage><history><date date-type="received"><day>20</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>22</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Xu et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec><title>BACKGROUND</title><p>To develop and validate a nomogram based on log of odds between the number of positive lymph node and the number of negative lymph node (LODDS) in predicting the overall survival (OS) and cancer specific survival (CSS) for epithelial ovarian cancer (EOC) patients.</p></sec><sec><title>MATERIALS AND METHODS</title><p>A total of 10,692 post-operative EOC patients diagnosed between 2004 and 2013 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database and randomly divided into training (n = 7,021) and validation (n = 3,671) cohorts. Multiple clinical pathological parameters were assessed and compared with outcomes. Parameters significantly correlating with outcomes were used to build a nomogram. Bootstrap validation was subsequently used to assess the predictive value of the model.</p></sec><sec><title>RESULTS</title><p>In the training set, age at diagnosis, race, marital status, tumor location, stage, grade and LODDS were correlated significantly with outcome in both the univariate and multivariate analyses and were used to develop a nomogram. The nomogram demonstrated good accuracy in predicting OS and CSS, with a bootstrap-corrected concordance index of 0.757 (95% CI, 0.746-0.768) for OS and 0.770 (95% CI, 0.759-0.782) for CSS. Notably, in this population our model performed favorably compared to the currently utilized Federation of Gynecology and Obstetrics (FIGO) model, with concordance indices of 0.699 (95% CI, 0.688-0.710, P &#x0003c; 0.05) and 0.719 (95% CI, 0.709- 0.730, P &#x0003c; 0.05) for OS and CSS, respectively. Using our nomogram in the validation cohort, the C-indices were 0.757 (95% CI, 0.741-0.773, P &#x0003c; 0.05, compared to FIGO) for OS and 0.762 (95% CI, 0.746-0.779, P &#x0003c; 0.05, compared to FIGO) for CSS.</p></sec><sec><title>CONCLUSIONS</title><p>LODDS works as an independent prognostic factor for predicting survival in patients with EOC regardless of the tumor stage. By incorporating LODDS, our nomogram may be superior to the currently utilized FIGO staging system in predicting OS and CSS among post-operative EOC patients.</p></sec></abstract><kwd-group><kwd>LODDS</kwd><kwd>epithelial ovarian cancer</kwd><kwd>nomogram</kwd><kwd>prognosis</kwd><kwd>SEER</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Ovarian cancer is the fifth leading cause of cancer-related death in women around the world. It is estimated that 1,4240 deaths will be attributed to this disease according to the National Cancer Institute [<xref rid="R1" ref-type="bibr">1</xref>]. As early-stage ovarian cancer is typically asymptomatic, most patients are diagnosed at more advanced stages, with associated dismal prognosis.</p><p>Traditionally, lymph node status has been considered to be an important predictor of outcomes for patients with ovarian cancer [<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R3" ref-type="bibr">3</xref>]. Presently, lymph node status is based on PLNs regardless of the number of resected lymph node (RLNs) in epithelial ovarian cancer (EOC) patient [<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R5" ref-type="bibr">5</xref>]. Consequently, the actual lymph node status may not adequately be reflected by the number of positive lymph node (PLNs).</p><p>Recently, ratio of PLNs to RLNs (LNR) and log of odds between PLNs and the number of negative lymph node (LODDS) have emerged as alternative predictive factors for outcomes in breast [<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R7" ref-type="bibr">7</xref>], gastric [<xref rid="R8" ref-type="bibr">8</xref>], pancreatic [<xref rid="R9" ref-type="bibr">9</xref>] and colorectal cancer [<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref>]. LNR is defined as the ratio of PLNs to RLNs. This parameter showed superiority to the lymph node status-based assessment system of N stage in several cancers, such as breast [<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R12" ref-type="bibr">12</xref>], gastric [<xref rid="R8" ref-type="bibr">8</xref>], and colon cancer [<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R14" ref-type="bibr">14</xref>]. LNR was also studied in ovarian cancer and found to be superior to both PLN and RLN number in predicting survival [<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R16" ref-type="bibr">16</xref>].</p><p>LODDS is defined as the log of odds between PLNs and the number of negative node. While this parameter has been validated in predicting survival for breast cancer, its utility in epithelial ovarian cancer is unknown [<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>]. We hypothesized that LODDS might be an important predictor of outcomes in epithelial ovarian cancer and that a nomogram incorporating LODDS may be superior in this respect to the currently-utilized FIGO score.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Clinical characteristics</title><p>The clinicopathological characteristics of these patients are listed in Table <xref ref-type="table" rid="T1">1</xref>. There were no significant differences between the training and validation cohorts. The median age at the time of diagnosis was 7 (49&#x02013;66) years in both cohorts. Most patients are married (56.8%). The majority of patients were Stage III at the time of surgery (47.5%). The most frequent histologic type was serous (56.5%). A majority of patients (98.8%) did not receive radiotherapy. The mean values for RLNs, PLNs, LNR and LODDS were 14.37, 1.35, 0.13 and -0.99 respectively. Additionally, the median survival time was 38 (90&#x02013;145) months.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Clinicopathological characteristics of EOC patients in the training and validation cohort</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="middle" rowspan="1" colspan="1">All patients (<italic>n</italic> =10692)</th><th align="center" valign="middle" rowspan="1" colspan="1">Training cohort (<italic>n</italic> = 7021)</th><th align="center" valign="middle" rowspan="1" colspan="1">Validation cohort (<italic>n</italic> = 3671)</th><th align="center" valign="middle" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Age at diagnosis, years</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Median (IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">57(49-66)</td><td align="center" valign="middle" rowspan="1" colspan="1">57(49-66)</td><td align="center" valign="middle" rowspan="1" colspan="1">57(49-66)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Year of diagnosis</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;2004-2007</td><td align="center" valign="middle" rowspan="1" colspan="1">3936</td><td align="center" valign="middle" rowspan="1" colspan="1">2559</td><td align="center" valign="middle" rowspan="1" colspan="1">1377</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;2007-2010</td><td align="center" valign="middle" rowspan="1" colspan="1">3261</td><td align="center" valign="middle" rowspan="1" colspan="1">2152</td><td align="center" valign="middle" rowspan="1" colspan="1">1109</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;2010-2013</td><td align="center" valign="middle" rowspan="1" colspan="1">3495</td><td align="center" valign="middle" rowspan="1" colspan="1">2310</td><td align="center" valign="middle" rowspan="1" colspan="1">1185</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Race</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;White</td><td align="center" valign="middle" rowspan="1" colspan="1">9045</td><td align="center" valign="middle" rowspan="1" colspan="1">5906</td><td align="center" valign="middle" rowspan="1" colspan="1">3139</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Black</td><td align="center" valign="middle" rowspan="1" colspan="1">521</td><td align="center" valign="middle" rowspan="1" colspan="1">354</td><td align="center" valign="middle" rowspan="1" colspan="1">167</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Other*</td><td align="center" valign="middle" rowspan="1" colspan="1">1126</td><td align="center" valign="middle" rowspan="1" colspan="1">761</td><td align="center" valign="middle" rowspan="1" colspan="1">365</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Marital status</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Married</td><td align="center" valign="middle" rowspan="1" colspan="1">6069</td><td align="center" valign="middle" rowspan="1" colspan="1">4042</td><td align="center" valign="middle" rowspan="1" colspan="1">2027</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Single</td><td align="center" valign="middle" rowspan="1" colspan="1">2085</td><td align="center" valign="middle" rowspan="1" colspan="1">1360</td><td align="center" valign="middle" rowspan="1" colspan="1">725</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Others#</td><td align="center" valign="middle" rowspan="1" colspan="1">2538</td><td align="center" valign="middle" rowspan="1" colspan="1">1619</td><td align="center" valign="middle" rowspan="1" colspan="1">919</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>FIGO Stage</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;I</td><td align="center" valign="middle" rowspan="1" colspan="1">4172</td><td align="center" valign="middle" rowspan="1" colspan="1">2745</td><td align="center" valign="middle" rowspan="1" colspan="1">1427</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;II</td><td align="center" valign="middle" rowspan="1" colspan="1">1445</td><td align="center" valign="middle" rowspan="1" colspan="1">937</td><td align="center" valign="middle" rowspan="1" colspan="1">508</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;III</td><td align="center" valign="middle" rowspan="1" colspan="1">5075</td><td align="center" valign="middle" rowspan="1" colspan="1">3339</td><td align="center" valign="middle" rowspan="1" colspan="1">1736</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Grade</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Well differentiate</td><td align="center" valign="middle" rowspan="1" colspan="1">1592</td><td align="center" valign="middle" rowspan="1" colspan="1">1051</td><td align="center" valign="middle" rowspan="1" colspan="1">541</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Moderately differentiate</td><td align="center" valign="middle" rowspan="1" colspan="1">2482</td><td align="center" valign="middle" rowspan="1" colspan="1">1581</td><td align="center" valign="middle" rowspan="1" colspan="1">901</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Poor differentiate</td><td align="center" valign="middle" rowspan="1" colspan="1">4482</td><td align="center" valign="middle" rowspan="1" colspan="1">2979</td><td align="center" valign="middle" rowspan="1" colspan="1">1503</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Tumor location</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;One site</td><td align="center" valign="middle" rowspan="1" colspan="1">6738</td><td align="center" valign="middle" rowspan="1" colspan="1">4427</td><td align="center" valign="middle" rowspan="1" colspan="1">2311</td><td align="center" valign="middle" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Bilateral site</td><td align="center" valign="middle" rowspan="1" colspan="1">3859</td><td align="center" valign="middle" rowspan="1" colspan="1">2534</td><td align="center" valign="middle" rowspan="1" colspan="1">1325</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Paired site</td><td align="center" valign="middle" rowspan="1" colspan="1">95</td><td align="center" valign="middle" rowspan="1" colspan="1">60</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Radiation</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="middle" rowspan="1" colspan="1">10565</td><td align="center" valign="middle" rowspan="1" colspan="1">6935</td><td align="center" valign="middle" rowspan="1" colspan="1">3630</td><td align="center" valign="middle" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">127</td><td align="center" valign="middle" rowspan="1" colspan="1">86</td><td align="center" valign="middle" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Histology</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Serous</td><td align="center" valign="middle" rowspan="1" colspan="1">6037</td><td align="center" valign="middle" rowspan="1" colspan="1">3977</td><td align="center" valign="middle" rowspan="1" colspan="1">2060</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Mucinous</td><td align="center" valign="middle" rowspan="1" colspan="1">1022</td><td align="center" valign="middle" rowspan="1" colspan="1">669</td><td align="center" valign="middle" rowspan="1" colspan="1">353</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Endometrioid</td><td align="center" valign="middle" rowspan="1" colspan="1">2518</td><td align="center" valign="middle" rowspan="1" colspan="1">1642</td><td align="center" valign="middle" rowspan="1" colspan="1">876</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Clear cell</td><td align="center" valign="middle" rowspan="1" colspan="1">1054</td><td align="center" valign="middle" rowspan="1" colspan="1">692</td><td align="center" valign="middle" rowspan="1" colspan="1">362</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Undifferentiated</td><td align="center" valign="middle" rowspan="1" colspan="1">61</td><td align="center" valign="middle" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>RLNs</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Mean (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.37(1-90)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.45(1-90)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.23(1-90)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>PLNs</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Mean (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.35(0-90)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.39(0-90)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26(0-57)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>LNR</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Mean (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.13(0.00-1.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.13(0.00-1.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.13(1.00-1.00)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>LODDS</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.86</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Mean (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.99(-2.26-2.26)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.98(-2.26-2.26)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.99(-2.16-1.95)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn_001"><label>*</label><p>Other including American Indian/AK Native, Asian/Pacific Islander.</p></fn><fn id="tfn_002"><label>#</label><p>Other including Widowed, Divorced, Separated and unknown</p></fn><p>Poor differentiate including Poor differentiate and undifferentiated</p><p>Abbreviations: RLNs, the number of lymph node examined; PLNs, the number of positive lymph node; LNR, positive lymph node ratio; LODDS, log of odds between the number of PLNs and number of negative nodes.</p></table-wrap-foot></table-wrap></sec><sec id="s2_2"><title>Factors associated with OS</title><p>Age at diagnosis, race, marital status, year of diagnosis, tumor location, tumor stage, tumor grade, histology, RLNs, PLNs, LNR, LODDS and treatment with radiation therapy were evaluated. All variables were significantly correlated with OS in univariate survival analysis (P &#x0003c; 0.05). Independent prognostic factors associated with OS identified from the multivariate analysis were subsequently incorporated into the nomogram (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Characteristics and multivariate analysis in the training set</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1">Variables</th><th colspan="2" align="center" valign="middle" rowspan="1">Univariate Analysis</th><th colspan="2" align="center" valign="middle" rowspan="1">Multivariate Analysis</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" valign="middle" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age at diagnosis, years</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04(1.03-1.04)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.028(1.024-1.032)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Race</td><td align="center" valign="middle" rowspan="1" colspan="1">0.90(0.84-0.97)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Other*</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;White</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.106(0.934-1.311)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.242</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Black</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.427(1.118-1.820)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Marital status</td><td align="center" valign="middle" rowspan="1" colspan="1">1.19(1.13-1.26)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;.001</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Others<sup>#</sup></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Married</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.818(0.734-0.911)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Single</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.907(0.780-1.053)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.200</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Stage</td><td align="center" valign="middle" rowspan="1" colspan="1">2.46(2.30-2.62)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;.001</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;III</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;I</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.280(0.238-0.330)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;II</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.469(0.395-0.557)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Grade</td><td align="center" valign="middle" rowspan="1" colspan="1">1.52(1.45-1.60)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;.001</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Poor differentiate</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Well differentiate</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.514(0.412-0.642)</td><td align="center" valign="middle" rowspan="1" colspan="1">.000</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Mediate differentiate</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.845(0.744- 0.961)</td><td align="center" valign="middle" rowspan="1" colspan="1">.010</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tumor location</td><td align="center" valign="middle" rowspan="1" colspan="1">1.45(1.39-1.51)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;.001</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Paired site</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;One site</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.897(0.591-1.361)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.609</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Bilateral site</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.154(0.762- 1.747)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.500</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Radiation</td><td align="center" valign="middle" rowspan="1" colspan="1">1.45(1.04-2.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Histology</td><td align="center" valign="middle" rowspan="1" colspan="1">0.68(0.65-0.72)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;.001</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Undifferentiated</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Serous</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.686(0.421-1.118)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.131</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Mucinous</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.193(0.701 -2.031)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.515</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Endometrioid</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.613(0.3691-.019)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.059</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Clear cell</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.983(0.587-1.647)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.949</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98(0.98-0.99)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.995(0.991-0.999)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLNs</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04(1.04-1.05)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LNR</td><td align="center" valign="middle" rowspan="1" colspan="1">4.67(4.15-5.27)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LODDS</td><td align="center" valign="middle" rowspan="1" colspan="1">2.10(1.99-2.21)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">1.359(1.269-1.454)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tfn_003"><label>*</label><p>Other including American Indian/AK Native, Asian/Pacific Islander.</p></fn><fn id="tfn_004"><label>#</label><p>Other including Widowed, Divorced, Separated and unknown.</p></fn><p>Poor differentiate including Poor differentiate and undifferentiated.</p><p>Abbreviations: CI, confidence interval; HR, hazard ratio; RLNs, the number of lymph node examined; PLNs, the number of positive lymph node; LNR, positive lymph node ratio; LODDS, log of odds between the number of PLNs and number of negative nodes.</p></table-wrap-foot></table-wrap></sec><sec id="s2_3"><title>Comparing the prognostic impact of RLNs, PLNs, LNR and LODDS</title><p>According to Figure <xref ref-type="fig" rid="F1">1</xref>, it is clearly that LODDS is a prognostic factor for EOC patients. The AUCs corresponding to inclusion of RLNs, PLNs, LNR and LODDS were 0.602, 0.625, 0.635 and 0.683 (respectively) for predicting OS and 0.590, 0.638, 0.646 and 0.686 (respectively) for predicting CSS (Figure <xref ref-type="fig" rid="F2">2</xref>), suggesting that LODDS may have superior discriminatory ability in predicting OS and CSS than the other parameters</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Comparison of the areas under curves of the number of RLNs, PLNs, LNR and LODDS to predict the impact of these factors on OS <bold>A.</bold> and CSS <bold>B.</bold> in the SEER training cohort. The green lines represent LODDS predicted survival, the blue lines represent the LNR predicted survival, the red line represent PLNs predicted survival and the black line represent RLNs predicted survival. Abbreviation: OS, overall survival; CSS, cancer specific survival; RLNs, the number of resected lymph node; PLNs, the number of positive lymph node; LNR, ratio of PLNs to RLNs; LODDS, log of odds between the number of positive lymph node (PLNs) and number of negative nodes.</p></caption><graphic xlink:href="oncotarget-08-8120-g001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The overall survival (OS) and cancer specific survival (CSS) curves of epithelial ovarian cancer patients according to the cutoff points based on LODDS. OS <bold>A.</bold> and CSS <bold>B.</bold> are plotted using the Kaplan-Meier method and analyzed by the log-rank test (P&#x0003c;0.001). Abbreviation: OS, overall survival; CSS, cancer specific survival; LODDS, log of odds between the number of positive lymph node (PLNs) and number of negative nodes.</p></caption><graphic xlink:href="oncotarget-08-8120-g002"/></fig></sec><sec id="s2_4"><title>Nomogram</title><p>All of the 11 parameters were associated with overall survival analyzed in the univariate analysis in EOC patients (Table <xref ref-type="table" rid="T2">2, P</xref> &#x0003c; 0.05). Nomograms for predicting 3- and 5 year OS and CSS were constructed based on the multivariate models by the backward method in the training cohort (Figure <xref ref-type="fig" rid="F3">3</xref>). By summing and locating the scores on the total score scale, the estimated probability of cancer-specific survival at 3- and 5-years could be determined. The bootstrap-corrected concordance indices were 0.75 (95% CI, 0.74-0.77) for predicting OS and 0.77 (95% CI, 0.76-0.78) for predicting CSS. Notably, the C-indices for FIGO stage were significantly lower: 0.699 (95% CI, 0.688-0.710, P &#x0003c; 0.05) for predicting OS and 0.719 (95% CI, 0.709- 0.730, P &#x0003c; 0.05) for predicting CSS.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Nomogram for predicting 3- and 5-year <bold>A.</bold> cancer specific survival (CSS) and <bold>B.</bold> overall survival (OS) of epithelial ovarian cancer patients. To use of the nomogram, you should assign the points of each characteristic of the patient by drawing a vertical line from that variable to the point scale, sum all the points and draw a vertical line from the total points scale to the 3- and 5-year CSS or OS to obtain the probability of death. Abbreviation: OS, overall survival; CSS, cancer specific survival; LODDS, log of odds between the number of positive lymph node (PLNs) and number of negative nodes.</p></caption><graphic xlink:href="oncotarget-08-8120-g003"/></fig></sec><sec id="s2_5"><title>Validation for nomogram</title><p>Validation of the nomogram was performed by 1000 bootstrap. In the training cohort, the Harrell's C-indices for the nomogram to predict OS and CSS were 0.757 (95% CI, 0.746-0.768) and 0.770 (95% CI, 0.759-0.782), respectively. Similarly, in the validation cohort, the C-indices to predict OS and CSS were 0.757 (95% CI, 0.741-0.773) and 0.762 (95% CI, 0.746-0.779). This finding implied that this model was reasonably accurate. The calibration plots demonstrated excellent correlation between predicted and observed values of OS and CSS in both training and validation cohorts (Figure <xref ref-type="fig" rid="F4">4</xref> &#x00026; Figure <xref ref-type="fig" rid="F5">5</xref>). Moreover, when comparing the c-index for OS and CSS based on either nomogram or FIGO stage, our nomogram showed better predictive probability than FIGO stage (Figure <xref ref-type="fig" rid="F6">6</xref>).</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The calibration plots predicting overall survival <bold>A-B.</bold> and cancer specific survival <bold>C-D.</bold> at 3- and 5-year point in the training cohort. The dashed line represents a perfect match between the nomogram predicted probability (x-axis) and the actual probability calculated by Kaplan-Meier analysis (y-axis). Abbreviation: OS, overall survival; CSS, cancer specific survival.</p></caption><graphic xlink:href="oncotarget-08-8120-g004"/></fig><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>The calibration plots predicting overall survival A-B. and cancer specific survival C-D. at 3- and 5-year point in the validation cohort. The dashed line represents a perfect match between the nomogram predicted probability (x-axis) and the actual probability calculated by Kaplan-Meier analysis (y-axis). Abbreviation: OS, overall survival; CSS, cancer specific survival.</p></caption><graphic xlink:href="oncotarget-08-8120-g005"/></fig><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Comparison of the areas under curves of nomogram and Stage to prediction of OS <bold>A, C.</bold> and CSS <bold>B, D.</bold> in the training (A, B) and validation cohort (C, D). The red lines represent nomogram predicted survival and the black lines represent the traditional stage predicted survival. Abbreviation: OS, overall survival; CSS, cancer specific survival.</p></caption><graphic xlink:href="oncotarget-08-8120-g006"/></fig></sec></sec><sec id="s3"><title>DISCUSSION</title><p>In this study, a novel nomogram based on LODDS was developed and validated to predict post-operative outcomes in epithelial ovarian cancer. In training and validation cohorts that were randomly extracted from the SEER database, this nomogram appears to predict OS and CSS more accurately than the currently utilized FIGO staging system.</p><p>A nomogram is a convenient tool for quantifying risk by incorporating and illustrating the relative importance of various prognostic factors and has been widely used in clinical oncology [<xref rid="R19" ref-type="bibr">19</xref>]. Several nomograms have been constructed to date to predict outcomes in ovarian cancer patients [<xref rid="R20" ref-type="bibr">20</xref>&#x02013;<xref rid="R23" ref-type="bibr">23</xref>]. To our knowledge, however, a nomogram based on LODDS for predicting outcomes in epithelial ovarian cancer patients has not been described.</p><p>It is well known that lymph node status can be used for post-operative risk stratification in epithelial ovarian cancer patients. The currently-utilized FIGO staging system uses PLNs in this calculus [<xref rid="R4" ref-type="bibr">4</xref>]. PLNs, however, remain a function of RLNs, and may not adequately reflect disease status in all situations [<xref rid="R24" ref-type="bibr">24</xref>]. For this reason, it is intuitive that RLNs and the number of negative lymph nodes should be simultaneously taken into consideration when formulating an adjuvant treatment plan. LODDS is an intuitive indicator that is reflective of both interrogated lymph nodes and the number of negative lymph nodes, and its use is supported by available data in other malignancies [<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>]. For the first time in the epithelial ovarian cancer population, we evaluated ROC curves based on RLNs, PLNs, LNR and LODDS, and found that LODDS has the highest AUC with superior sensitivity and specificity compared to other factors.</p><p>We subsequently constructed a nomogram where patients were randomly assigned to either training or validation cohorts to avoid selection bias.</p><p>To date, several nomograms have been constructed for predicting outcomes in EOC patients that possess superior predictive ability compared to the widely-utilized FIGO staging system. In 2012, Barlin and colleagues evaluated for parameters predicting disease-specific survival after surgery based on outcomes in 478 EOC patients [<xref rid="R25" ref-type="bibr">25</xref>]. Lee et al. evaluated parameters predicting survival in patients initially responsive to a platinum-based regimen subsequently demonstrating recurrent disease in 2013 [<xref rid="R26" ref-type="bibr">26</xref>]. More recent studies evaluated survival based on surgery type [<xref rid="R22" ref-type="bibr">22</xref>, <xref rid="R23" ref-type="bibr">23</xref>].</p><p>However, all of these nomograms were based on very limited cases. Thus, it is unclear whether it can be generally applied. Actually, sufficient data included is useful to improve the accuracy of nomogram. Compared with previous nomogram, our nomogram was developed and validated based both on a larger population on seer database which included several departments and racial might be universally applied.</p><p>The C-indexes for the nomograms to predict OS and CSS were 0.757, 0.770 respectively in the training cohort and 0.74, 0.76 respectively in the validation cohort which higher than FIGO stage. Therefore, this nomogram model has less bias and better accuracy when applied in practical work.</p><p>Improving the accuracy of the survival estimation is exceedingly important for clinical decision. Several advantages can be obtained by using nomogram. Firstly, as our nomogram performed better than FIGO stage on prediction of individual survival, it would be useful for designing postoperative treatment and the probability of excessive treatment would be reduced. Secondly, because our nomogram could calculate 3&#x02013;year and 5&#x02013;year survival rate individually, a more reasonable follow&#x02013;up schedule could be obtained. Thirdly, individual consultant is in need of nomogram. The survival of EOC could not be accurately predicted by FIGO stage. In comparison, our nomogram can provide individualized estimation for EOC cancer patients.</p><p>Although the nomogram model demonstrated good accuracy for predicting OS and CSS, there are several limitations to the data which must be considered. Firstly, this study based on retrospective data which has inevitable inherent bias. Secondly, some prognostic factors like chemotherapy data and tumor marker like CA-125 which were not available. Finally, external validation should be carried out. In summary, our study demonstrated that LODDS was independently associated with the prognosis of EOC patients. We developed and validated a nomogram based on LODDS to estimate 3- and 5-year OS and CSS among EOC which could successfully stratify patients according to their OS and CSS. This clinically useful tool uses available clinicopathologic factors to estimate the probability of OS and CSS, which can further contribute to the individualized clinical decision.</p></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><p>Data were collected from the SEER program of the National Cancer Institute consisting of 18 population based cancer registries, which covers approximately 28% of the US population (<ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov/">http://seer.cancer.gov/</ext-link>). All pathologically-confirmed and surgically-treated EOC patients from the SEER database between 2004 and 2013 were included. Patients with unknown or incomplete lymph node status were excluded. A total of 10,692 patients with histologically confirmed EOC were obtained. These cases were then randomized to two groups (training cohort, N=7,021 and validation cohort, N=3,671). Patients in American Indian/Alaskan Native and Asian/Pacific Islanders were recorded as &#x0201c;other&#x0201d; under race. Widowed, Divorced, Separated and unknown were recorded as &#x0201c;other&#x0201d; under marital status. Poor differentiate and undifferentiated were classified as the poor differentiate group.</p><p>Our study was approved by Ethical Committee of Sun Yat-Sen University Cancer Center. Cancer is a reportable disease in every state in the US, informed patient consent is not required for the data released by the SEER database.</p><sec id="s4_1"><title>Statistical analysis</title></sec><sec id="s4_2"><title>Construction of the nomogram</title><p>Eligible patients were randomly divided into training (n = 7,021) and validation cohorts (n= 3,671) to establish and validate the nomogram. The follow-up time was defined as the time between the surgery and the last follow-up time. OS was defined as the time between the surgery and cancer-specific death or the last follow-up time. CSS was defined as the time between the surgery and cancer-specific death. The Kaplan-Meier method and Cox regression analysis were used to determine factors associated with survival. Significant factors were used to construct the nomogram for OS and CSS.</p></sec><sec id="s4_3"><title>Validation of the nomogram</title><p>1000 bootstrap were performed for validation. Calibration diagrams were created with the marginal estimate versus model average predictive probability. The predictions should fall on a 45-degree diagonal line in a perfectly calibrated model. An index of probability of concordance (C-index) between predicted probability and actual outcome was calculated to evaluate the predicting ability and discrimination of the model [<xref rid="R27" ref-type="bibr">27</xref>]. The value of the C-index ranges from 0.5 to 1.0, with 0.5 indicating random chance and 1.0 indicating a perfectly corrected discrimination.</p><p>Statistical analysis was performed using SPSS 19.0 (SPSS, Chicago, IL, USA) and R version 3.3.0 software (Institute for Statistics and Mathematics, Vienna, Austria;<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">www.r-project.org</ext-link>). The &#x0201c;rms&#x0201d; R library by Harrell (<ext-link ext-link-type="uri" xlink:href="http://cran.r-project.org/web/packages/rms">cran.r-project.org/web/packages/rms</ext-link>) was used to construct survival models [<xref rid="R28" ref-type="bibr">28</xref>]. P value less than 0.05 were considered statistically significant.</p></sec></sec></body><back><ack><p>This work was supported by the National Natural Science Foundation of China (Grant No. 81560423), the Science and Technology Project of Guangdong Province (2015B050501005; 2014B050504004) and the Science and Technology Project of Xinjiang Autonomous Region.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>All authors claim that there are no conflicts of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2016</article-title><source>CA</source><year>2016</year><volume>66</volume><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">26742998</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prader</surname><given-names>S</given-names></name><name><surname>Harter</surname><given-names>P</given-names></name><name><surname>Grimm</surname><given-names>C</given-names></name><name><surname>Traut</surname><given-names>A</given-names></name><name><surname>Waltering</surname><given-names>KU</given-names></name><name><surname>Alesina</surname><given-names>PF</given-names></name><name><surname>Heikaus</surname><given-names>S</given-names></name><name><surname>Ataseven</surname><given-names>B</given-names></name><name><surname>Heitz</surname><given-names>F</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><etal/></person-group><article-title>Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer</article-title><source>Gynecologic oncology</source><year>2016</year><volume>141</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">26972337</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwase</surname><given-names>H</given-names></name><name><surname>Takada</surname><given-names>T</given-names></name><name><surname>Iitsuka</surname><given-names>C</given-names></name><name><surname>Nomura</surname><given-names>H</given-names></name><name><surname>Abe</surname><given-names>A</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Takizawa</surname><given-names>K</given-names></name></person-group><article-title>Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients</article-title><source>Journal of gynecologic oncology</source><year>2015</year><volume>26</volume><fpage>303</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">26197771</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ismail</surname><given-names>E</given-names></name><name><surname>Kornovski</surname><given-names>Y</given-names></name></person-group><article-title>SURGICAL STAGING OF OVARIAN CANCER (I FIGO STAGE): IGCS-0018 Ovarian Cancer</article-title><source>International journal of gynecological cancer</source><year>2015</year><volume>25</volume><fpage>52</fpage><pub-id pub-id-type="pmid">25955932</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasimli</surname><given-names>K</given-names></name><name><surname>Braicu</surname><given-names>EI</given-names></name><name><surname>Nassir</surname><given-names>M</given-names></name><name><surname>Richter</surname><given-names>R</given-names></name><name><surname>Babayeva</surname><given-names>A</given-names></name><name><surname>Chekerov</surname><given-names>R</given-names></name><name><surname>Darb-Esfahani</surname><given-names>S</given-names></name><name><surname>Sehouli</surname><given-names>J</given-names></name><name><surname>Muallem</surname><given-names>MZ</given-names></name></person-group><article-title>Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network</article-title><source>Annals of surgical oncology</source><year>2016</year><volume>23</volume><fpage>1279</fpage><lpage>1286</lpage><pub-id pub-id-type="pmid">26832880</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>XS</given-names></name><name><surname>Tang</surname><given-names>HL</given-names></name><name><surname>Xie</surname><given-names>XH</given-names></name><name><surname>Li</surname><given-names>LS</given-names></name><name><surname>Kong</surname><given-names>YN</given-names></name><name><surname>Wu</surname><given-names>MQ</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>WD</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name></person-group><article-title>Metastatic axillary lymph node ratio (LNR) is prognostically superior to pN staging in patients with breast cancer&#x02014;results for 804 Chinese patients from a single institution</article-title><source>Asian Pac J Cancer Prev</source><year>2013</year><volume>14</volume><fpage>5219</fpage><lpage>5223</lpage><pub-id pub-id-type="pmid">24175804</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name></person-group><article-title>Development and validation of a prognostic nomogram based on the log odds of positive lymph nodes (LODDS) for breast cancer</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>21046</fpage><lpage>21053</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.8091</pub-id><pub-id pub-id-type="pmid">26992235</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>CW</given-names></name><name><surname>Wang</surname><given-names>LW</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>GF</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Pang</surname><given-names>DW</given-names></name></person-group><article-title>Combined features based on MT1-MMP expression, CD11b + immunocytes density and LNR predict clinical outcomes of gastric cancer</article-title><source>Journal of translational medicine</source><year>2013</year><volume>11</volume><fpage>153</fpage><pub-id pub-id-type="pmid">23787075</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M</surname><given-names>La Torre</given-names></name><name><surname>Nigri</surname><given-names>G</given-names></name><name><surname>Petrucciani</surname><given-names>N</given-names></name><name><surname>Cavallini</surname><given-names>M</given-names></name><name><surname>Aurello</surname><given-names>P</given-names></name><name><surname>Cosenza</surname><given-names>G</given-names></name><name><surname>Balducci</surname><given-names>G</given-names></name><name><surname>Ziparo</surname><given-names>V</given-names></name><name><surname>Ramacciato</surname><given-names>G</given-names></name></person-group><article-title>Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph nodes</article-title><source>Pancreatology</source><year>2014</year><volume>14</volume><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">25062879</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>YX</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>ZN</given-names></name><name><surname>Tong</surname><given-names>LL</given-names></name><name><surname>Xu</surname><given-names>YY</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Xing</surname><given-names>CZ</given-names></name><name><surname>Xu</surname><given-names>HM</given-names></name></person-group><article-title>Which is the most suitable classification for colorectal cancer, log odds, the number or the ratio of positive lymph nodes?</article-title><source>PloS one</source><year>2011</year><volume>6</volume><fpage>e28937</fpage><pub-id pub-id-type="pmid">22174929</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozawa</surname><given-names>T</given-names></name><name><surname>Ishihara</surname><given-names>S</given-names></name><name><surname>Sunami</surname><given-names>E</given-names></name><name><surname>Kitayama</surname><given-names>J</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name></person-group><article-title>Log odds of positive lymph nodes as a prognostic indicator in stage IV colorectal cancer patients undergoing curative resection</article-title><source>Journal of surgical oncology</source><year>2015</year><volume>111</volume><fpage>465</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">25690280</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>JI</given-names></name><name><surname>Park</surname><given-names>W</given-names></name><name><surname>Choi</surname><given-names>DH</given-names></name><name><surname>Huh</surname><given-names>SJ</given-names></name><name><surname>Nam</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Kil</surname><given-names>WH</given-names></name><name><surname>Im</surname><given-names>YH</given-names></name><name><surname>Ahn</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Limited Supraclavicular Radiation Field in Breast Cancer With &#x0003e;/= 10 Positive Axillary Lymph Nodes</article-title><source>Clinical breast cancer</source><year>2016</year><volume>16</volume><fpage>e15</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">26732519</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Amri</surname><given-names>R</given-names></name><name><surname>Klos</surname><given-names>CL</given-names></name><name><surname>Bordeianou</surname><given-names>L</given-names></name><name><surname>Berger</surname><given-names>DL</given-names></name></person-group><article-title>The prognostic value of lymph node ratio in colon cancer is independent of resection length</article-title><source>American journal of surgery</source><year>2016</year></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>A</surname><given-names>Zare Mirzaei</given-names></name><name><surname>Abdorrazaghi</surname><given-names>F</given-names></name><name><surname>Lotfi</surname><given-names>M</given-names></name><name><surname>B</surname><given-names>Kazemi Nejad</given-names></name><name><surname>Shayanfar</surname><given-names>N</given-names></name></person-group><article-title>Prognostic Value of Lymph Node Ratio in Comparison to Lymph Node Metastases in Stage III Colon Cancer</article-title><source>Iranian journal of pathology</source><year>2015</year><volume>10</volume><fpage>127</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">26351473</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>ZY</given-names></name><name><surname>Li</surname><given-names>FY</given-names></name><name><surname>Sun</surname><given-names>JY</given-names></name><name><surname>Lin</surname><given-names>HX</given-names></name><name><surname>Wu</surname><given-names>SG</given-names></name><name><surname>Chen</surname><given-names>QH</given-names></name></person-group><article-title>Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>7952</fpage><lpage>7959</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6911</pub-id><pub-id pub-id-type="pmid">26788911</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ataseven</surname><given-names>B</given-names></name><name><surname>Grimm</surname><given-names>C</given-names></name><name><surname>Harter</surname><given-names>P</given-names></name><name><surname>Prader</surname><given-names>S</given-names></name><name><surname>Traut</surname><given-names>A</given-names></name><name><surname>Heitz</surname><given-names>F</given-names></name><name><surname>du Bois</surname><given-names>A</given-names></name></person-group><article-title>Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer</article-title><source>Gynecologic oncology</source><year>2014</year><volume>135</volume><fpage>435</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">25312398</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LJ</given-names></name><name><surname>Chung</surname><given-names>KP</given-names></name><name><surname>Chang</surname><given-names>YJ</given-names></name><name><surname>Chang</surname><given-names>YJ</given-names></name></person-group><article-title>Ratio and log odds of positive lymph nodes in breast cancer patients with mastectomy</article-title><source>Surgical oncology</source><year>2015</year><volume>24</volume><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">26055316</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>SG</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>JY</given-names></name><name><surname>Li</surname><given-names>FY</given-names></name><name><surname>Lin</surname><given-names>HX</given-names></name><name><surname>He</surname><given-names>ZY</given-names></name></person-group><article-title>Number of negative lymph nodes should be considered for incorporation into staging for breast cancer</article-title><source>American journal of cancer research</source><year>2015</year><volume>5</volume><fpage>844</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">25973321</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>CF</given-names></name><name><surname>Zhang</surname><given-names>SL</given-names></name><name><surname>Dai</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>DW</given-names></name></person-group><article-title>A nomogram to predict Gleason sum upgrading of clinically diagnosed localized prostate cancer among Chinese patients</article-title><source>Chinese journal of cancer</source><year>2014</year><volume>33</volume><fpage>241</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">24559852</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerestein</surname><given-names>CG</given-names></name><name><surname>Eijkemans</surname><given-names>MJ</given-names></name><name><surname>Bakker</surname><given-names>J</given-names></name><name><surname>Elgersma</surname><given-names>OE</given-names></name><name><surname>van der Burg</surname><given-names>ME</given-names></name><name><surname>Kooi</surname><given-names>GS</given-names></name><name><surname>Burger</surname><given-names>CW</given-names></name></person-group><article-title>Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer</article-title><source>Anticancer research</source><year>2011</year><volume>31</volume><fpage>4043</fpage><lpage>4049</lpage><pub-id pub-id-type="pmid">22110240</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachance</surname><given-names>JA</given-names></name><name><surname>Choudhri</surname><given-names>AF</given-names></name><name><surname>Sarti</surname><given-names>M</given-names></name><name><surname>Modesitt</surname><given-names>SC</given-names></name><name><surname>Jazaeri</surname><given-names>AA</given-names></name><name><surname>Stukenborg</surname><given-names>GJ</given-names></name></person-group><article-title>A nomogram for estimating the probability of ovarian cancer</article-title><source>Gynecologic oncology</source><year>2011</year><volume>121</volume><fpage>2</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21269667</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shim</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>SO</given-names></name><name><surname>Kim</surname><given-names>SN</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Kim</surname><given-names>YT</given-names></name><name><surname>Nam</surname><given-names>JH</given-names></name></person-group><article-title>Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients</article-title><source>Gynecologic oncology</source><year>2015</year><volume>136</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">25448457</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieuwenhuyzen-de Boer</surname><given-names>GM</given-names></name><name><surname>Gerestein</surname><given-names>CG</given-names></name><name><surname>Eijkemans</surname><given-names>MJ</given-names></name><name><surname>Burger</surname><given-names>CW</given-names></name><name><surname>Kooi</surname><given-names>GS</given-names></name></person-group><article-title>Nomogram for 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer</article-title><source>European journal of gynaecological oncology</source><year>2016</year><volume>37</volume><fpage>63</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">27048112</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Ataseven</surname><given-names>B</given-names></name><name><surname>Harter</surname><given-names>P</given-names></name><name><surname>Grimm</surname><given-names>C</given-names></name><name><surname>Heitz</surname><given-names>F</given-names></name><name><surname>Heikaus</surname><given-names>S</given-names></name><name><surname>Traut</surname><given-names>A</given-names></name><name><surname>Kahl</surname><given-names>A</given-names></name><name><surname>Kurzeder</surname><given-names>C</given-names></name><name><surname>Prader</surname><given-names>S</given-names></name><name><surname>du Bois</surname><given-names>A</given-names></name></person-group><article-title>The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?</article-title><source>Gynecologic oncology</source><year>2016</year></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barlin</surname><given-names>JN</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Hill</surname><given-names>EK</given-names></name><name><surname>Zivanovic</surname><given-names>O</given-names></name><name><surname>Kolev</surname><given-names>V</given-names></name><name><surname>Levine</surname><given-names>DA</given-names></name><name><surname>Sonoda</surname><given-names>Y</given-names></name><name><surname>Abu-Rustum</surname><given-names>NR</given-names></name><name><surname>Huh</surname><given-names>J</given-names></name><name><surname>Barakat</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer</article-title><source>Gynecologic oncology</source><year>2012</year><volume>125</volume><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">22155261</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Simes</surname><given-names>RJ</given-names></name><name><surname>Brown</surname><given-names>C</given-names></name><name><surname>Gebski</surname><given-names>V</given-names></name><name><surname>Pfisterer</surname><given-names>J</given-names></name><name><surname>Swart</surname><given-names>AM</given-names></name><name><surname>Berton-Rigaud</surname><given-names>D</given-names></name><name><surname>Plante</surname><given-names>M</given-names></name><name><surname>Skeie-Jensen</surname><given-names>T</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><etal/></person-group><article-title>A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer</article-title><source>Annals of oncology</source><year>2013</year><volume>24</volume><fpage>937</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">23104722</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolbers</surname><given-names>M</given-names></name><name><surname>Koller</surname><given-names>MT</given-names></name><name><surname>Witteman</surname><given-names>JC</given-names></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name></person-group><article-title>Prognostic models with competing risks: methods and application to coronary risk prediction</article-title><source>Epidemiology</source><year>2009</year><volume>20</volume><fpage>555</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">19367167</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunez</surname><given-names>E</given-names></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name><name><surname>Nunez</surname><given-names>J</given-names></name></person-group><article-title>[Regression modeling strategies]</article-title><source>Revista espanola de cardiologia</source><year>2011</year><volume>64</volume><fpage>501</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">21531065</pub-id></element-citation></ref></ref-list></back></article>